The DOI matches its Crossref record; 325 of the 325 references it cites were found in a registry or an index.
Clinical Translation of Nanomedicine
Open accessAbstract
1. Introduction Nanomedicine, the application of nanotechnology to health and medicine, is a relatively new area of interdisciplinary science. The field involves a wide range of scientific disciplines, including physics, chemistry, engineering, biology, and medical science. The term nanomedicine can be traced back to the late 1990s and first appeared in research publications in the year 2000.1 Despite the wide adoption of the term nanomedicine, its definition varies among experts in this area.2 Some define nanomedicine broadly as any science that involves matters that are nanoscale. For example, the European Science Foundation in 2004 defined nanomedicine as “the science and technology of diagnosing, treating, and preventing disease and traumatic injury, of relieving pain, and of preserving and improving human health, using molecular tools and molecular knowledge of the human body”.2 While such a broad definition is all encompassing, it can be confusing. For example, such a definition would include traditional scientific fields such as molecular biology as part of nanomedicine, because molecules such as nucleic acids and proteins are also nanoscale materials. However, scientists have been studying these molecules decades before the term nanomedicine was even coined, and their research generally does not take advantage of unique properties that only exist for nanomaterials. A narrower definition of nanomedcine is the application of nanoscale material in medicine that takes advantage of the nanomaterial's unique properties.1 This Review will adopt this narrower definition in our discussion of the clinical translation of nanomedicine. Nanomedicine has made a rapid and broad impact on healthcare. Despite being only several decades old, research in nanomedicine has already led to the development of a wide range of products including therapeutics, diagnostic imaging agents, in vitro diagnostics, and medical devices. There are more than 200 nanomedicine products that have been either approved or are under clinical investigation.3 On the other hand, successful clinical translation is a challenging process. It requires extensive preclinical research, carefully selected clinical indication, proper design of clinical trials, and the successful completion of these trials. Mistakes in clinical translation can be unforgiving. Unlike preclinical research where there are many if not unlimited chances of generating a successful study, a single failed clinical trial can doom a drug's translation. Hay et al. recently showed that the eventual success rate of approval for therapeutics entering phase I trial is only about 10%.4 Because of this sobering statistic, it is important for translational researchers to fully understand the clinical translation process and to develop a successful translation strategy in the early stages of research. As compared to diagnostics and devices, clinical translation of therapeutics is arguably the most challenging. The typical clinical translation path for a new drug starts with investigators generating robust preclinical data to demonstrate the safety and efficacy of the new drug to enable an investigational new drug (IND) application with the Food and Drug Administration (FDA).5 Once the FDA has approved the IND, the therapeutic will be evaluated in a first-in-human or a phase I clinical trial. The goal of such a study is to determine the safety profile and pharmacology of the drug. It will result in a dose and schedule for further clinical investigation, or the recommended phase 2 dose (RP2D). The typical phase I trial design used a “3 + 3” cohort expansion design.6 This design assumes toxicity increases with dose, and it aims to determine the dose level that has less than 1/3 chance of a dose-limiting toxicity (DLT).7 In general, such a trial starts with a low drug dose. If none of the three patients receiving this dose experiences a DLT, another three patients will be treated at the next higher dose level. If one of the three patients experiences a DLT, then three more patients will be treated at the same dose level. Dose escalation continues until two patients among a cohort of three to six patients experience DLT. The RP2D is the dose level just below this level. Dose escalation typically follows a modified Fibonacci sequence where dose increments decrease as the tested dose increases. Other types of phase I designs include the accelerated titration designs, Bayesian models-based designs, and many others.7 Each design has advantages and disadvantages, and investigators have to choose the design that best fits the therapeutic. The goal of a phase II clinical trial is to examine the effectiveness of a drug or treatment. Secondarily, it will acquire more data on the toxicity and tolerability of the therapeutic. Therapeutics will progress to phase III clinical investigation only if they can demonstrate efficacy in phase II. The designs of phase II trials are either single-arm trials or randomized trials.8 Single-arm trials are cheaper, require fewer patients, and are typically easier to accrue. However, the outcome is less reliable as there is no comparison/control arm, and data are more susceptible to bias. Data from randomized phase II trials are more predictive of phase III results. However, it requires more patients and can be more difficult to accrue. Randomized phase II trials do not replace phase III investigations. Although they are randomized, patients are generally stratified on the basis of very few variables, such as age, sex, and disease status in phase II trials to keep the accrual goal low. Randomized phase III trials stratify patients on the basis of a large number of variables, which leads to less bias and more robust data. Because of the stratifications, the sample size required for phase III investigation is much higher than that of randomized phase II trials. The goal of randomized phase III trials is to demonstrate that the investigational treatment is more effective than the “gold standard” treatment. In general, phase III data are required for FDA approval. However, in select cases where there are robust data and unmet clinical needs, conditional approval can be granted on the basis of phase II data or interim phase III data. The FDA has a range of programs to speed up the approval process, including accelerated approvals and the recent “break through therapy” designation.9 There is a “short-cut” to FDA approval for agents that are based on already approved drugs. This pathway is called the 505(b)(2) pathway. The process of timeline for 505(b)(2) is much more abbreviated when compared to a typical approval process. For nanomedicine, this pathway will typically require that the exact nanoparticle platform is already approved with another agent and the drug being delivered by the nanoparticle is also approved. Past examples of this include the approval of liposomal bupivacaine with the DepoFoam liposome platform. The FDA was granted the authority to regulate medical devices in 1976.10 The approval process for medical devices is very different from that of drugs. First, for devices that predate May 28, 1976, these devices can remain on the market without needing approval. For the devices entering the market after that date, they are classified into different classes (I, II, and III) on the basis of their risks (Table 1).10 Class I devices are of low risk and are generally exempt from premarket notification (referred to as 510(k)) and may even be exempt from compliance with the good manufacturing practice requirement. Class II devices typically will require 510(k) submission before marketing. Class III devices are subject to the most stringent regulatory controls. Their approval will require a premarket approval (PMA) application. The 510(k) pathway is for devices that can be compared to existing, legally marketed “predicate” devices. The new device needs to be shown to be at least as safe and as effective as the “predicate” device. For devices that do not have a “predicate” device with which to compare, they are classified as class III and will need PMA. PMA needs to include scientific evidence that the device is safe and effective for its intended use. Unlike therapeutics where approvals generally require large randomized studies, scientific evidence for devices can include randomized controlled trials, single-arm studies, well-documented case series, and reports of significant human experience. For new devices that pose significant potential risks, an investigational device exemption (IDE) application is required prior to clinical investigation. Overall, the approval process is much simpler for devices than for therapeutics. Table 1 Summary of the FDA Device Regulation Processa In this Review, we will examine preclinical evidence, chosen clinical path to translation, and clinical data of clinically approved nanomedicine products. We will also discuss the clinical data on nanomedicines that are under clinical investigation or failed clinical translation. Each of these clinical nanomedicine products has a unique clinical translation story. By examining this body of evidence, we aim to formulate important concepts that are keys to nanomedicine's clinical translation and to identify challenges. Such concepts will facilitate the translation of future nanomedicine products.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Items 201–325 of 325
Liposome-Encapsulated Amphotericin B for Treatment of Disseminated Candidiasis in Neutropenic Mice
Lopez‐Berestein, G., Hopfer, R. L., Mehta, R. T., Mehta, K., Hersh, E. M., & Juliano, R. L. (1984) · The Journal of Infectious Diseases · doi:10.1093/infdis/150.2.278 · Cited by 125
O'Brien, M. E. R., Socinski, M. A., Popovich, A. Y., Bondarenko, I., Tomova, A., ̆ı, B. T. B., Hotko, Y., Ganul, V. L., Kostinsky, I. Y., Eisenfeld, A. J., et al. (2008) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e31817c6b68 · Cited by 125
Sabbatini, P. J., Aghajanian, C. A., Dizon, D. S., Anderson, S., Dupont, J., Brown, J. V., Peters, W. A., Jacobs, A. D., Mehdi, A., Rivkin, S. E., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.12.043 · Cited by 125
Martín‐Carbonero, L., Barrios, A., Saballs, P., Sirera, G., Santos, J. S., Muñoz, R. P., Valencia, E., Alegre, M., Podzamczer, D., & González‐Lahoz, J. (2004) · AIDS · doi:10.1097/01.aids.0000131385.60974.b9 · Cited by 122
Coleman, R. L., Brady, W. E., McMeekin, D. S., Rose, P. G., Soper, J. T., Lentz, S. S., Hoffman, J. S., & Shahin, M. S. (2011) · Gynecologic Oncology · doi:10.1016/j.ygyno.2011.03.036 · Cited by 122
Rizvi, N. A., Riely, G. J., Azzoli, C. G., Miller, V. A., Ng, K., Fiore, J. J., Chia, G., Brower, M., Heelan, R. T., Hawkins, M., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.10.8605 · Cited by 121
Blood Pool MR Angiography of Aortic Stent-Graft Endoleak
Ersoy, H., Jacobs, P., Kent, C. K., & Prince, M. R. (2004) · American Journal of Roentgenology · doi:10.2214/ajr.182.5.1821181 · Cited by 119
Endo, K., Ueno, T., Kondo, S., Wakisaka, N., Murono, S., Itō, M., Kataoka, K., Kato, Y., & Yoshizaki, T. (2012) · Cancer Science · doi:10.1111/cas.12079 · Cited by 119
Bowden, R. A., Cays, M., Gooley, T. A., Mamelok, R. D., & van Burik, J. (1996) · The Journal of Infectious Diseases · doi:10.1093/infdis/173.5.1208 · Cited by 117
Yoo, G., Hung, M., Lopez‐Berestein, G., LaFollette, S., Ensley, J. F., Carey, M., Batson, E. P., Reynolds, T. C., & Murray, J. L. (2001) · PubMed · Cited by 116
Bernstein, D. I., Stanberry, L. R., Sacks, S. H., Ayisi, N. K., Gong, Y., Ireland, J., Mumper, R. J., Holan, G., Matthews, B. R., McCarthy, T. D., et al. (2003) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.47.12.3784-3788.2003 · Cited by 116
Bernd, H., De Kerviler, E., Gaillard, S., & Bonnemain, B. (2009) · Investigative Radiology · doi:10.1097/rli.0b013e3181a0068b · Cited by 115
Size of thermosensitive liposomes influences content release
Hossann, M., Wang, T., Wiggenhorn, M., Schmidt, R., Zengerle, A., Winter, G., Eibl, H., Peller, M., Reiser, M. F., Issels, R. D., et al. (2010) · Journal of Controlled Release · doi:10.1016/j.jconrel.2010.08.013 · Cited by 114
Tsukioka, Y., Matsumura, Y., Hamaguchi, T., 小池浩代, Moriyasu, F., & Kakizoe, T. (2002) · Japanese Journal of Cancer Research · doi:10.1111/j.1349-7006.2002.tb01217.x · Cited by 114
Li, C., Newman, R. A., Wu, Q.-P., Shi, K., Chen, W., Hutto, T. Y., Kan, Z., Brannan, M. D., Charnsangavej, C., & Wallace, S. (2000) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s002800000168 · Cited by 114
Antitumor activity of poly(L-glutamic acid)-paclitaxel on syngeneic and xenografted tumors.
Li, C., Price, J. E., Milas, L., Hunter, N. R., Shi, K., Yu, D. F., Charnsangavej, C., & Wallace, S. (1999) · PubMed · Cited by 114
Bone marrow: ultrasmall superparamagnetic iron oxide for MR imaging.
Senéterre, E., Weissleder, R., Jaramillo, D., Reimer, P., Lee, A. S., Brady, T. J., & WITTENBERG, J. (1991) · Radiology · doi:10.1148/radiology.179.2.2014305 · Cited by 109
Boddy, A. V., Plummer, E. R., Todd, R., Sludden, J., Griffin, M., Robson, L., Cassidy, J., Bissett, D., Bernareggi, A., Verrill, M. W., et al. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-0803 · Cited by 108
Phase II study of liposomal cisplatin (SPI-77) in platinum-sensitive recurrences of ovarian cancer.
Seetharamu, N., Kim, E., Höchster, H. S., Martin, F., & Muggia, F. M. (2010) · PubMed · Cited by 107
Pharmacokinetics of liposomal amphotericin B (Ambisome) in critically ill patients
Heinemann, V., Bosse, D., Jehn, U., Kähny, B., Wachholz, K., Debus, A., Scholz, P., Kolb, H. J., & Wilmanns, W. (1997) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.41.6.1275 · Cited by 107
Řı́hová, B., Etrych, T., Pechar, M., Jelínková, M., Šťastný, M., Hovorka, O., Kovář, M., & Ulbrich, K. (2001) · Journal of Controlled Release · doi:10.1016/s0168-3659(01)00320-0 · Cited by 106
Li, C., Shi, K., Wu, Q., Tansey, W., Hunter, N. R., Buchmiller, L., Milas, L., Charnsangavej, C., & Wallace, S. (2000) · PubMed · Cited by 102
Treatment of Patients With Acquired Immunodeficiency Syndrome and Associated Manifestations
Kaplan, L. D. (1987) · JAMA · doi:10.1001/jama.1987.03390100105034 · Cited by 100
Measurement of Fraction Unbound Paclitaxel in Human Plasma
Brouwer, E., Verweij, J., De Bruijn, P., Loos, W. J., Pillay, M., Buijs, D., & Sparreboom, A. (2000) · Drug Metabolism and Disposition · doi:10.1016/s0026-895x(24)12040-8 · Cited by 98
Kottschade, L. A., Suman, V. J., AMATRUDA, T. T., McWilliams, R. R., Mattar, B. I., Nikcevich, D. A., Behrens, R. J., Fitch, T. R., Jaslowski, A. J., & Markovic, S. N. (2010) · Cancer · doi:10.1002/cncr.25659 · Cited by 98
Safety, Tolerability, and Pharmacokinetics of SPL7013 Gel (VivaGel®): A Dose Ranging, Phase I Study
O'Loughlin, J. A., Millwood, I. Y., McDonald, H. M., et al. (2010) · Sexually Transmitted Diseases · doi:10.1097/olq.0b013e3181bc0aac · Cited by 97
Gabizon, A., Tzemach, D., Horowitz, A. T., Shmeeda, H., Yeh, J., & Zalipsky, S. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-1547 · Cited by 97
Prevention of MDR development in leukemia cells by micelle-forming polymeric surfactant
Sharma, A. K., Zhang, L., Li, S., Kelly, D. L., Alakhov, V. Y., Batrakova, E. V., & Kabanov, A. V. (2008) · Journal of Controlled Release · doi:10.1016/j.jconrel.2008.07.031 · Cited by 96
Doxorubicin (adriamycin) cardiomyopathy.
Saltiel, E., & McGuire, W. P. (1983) · PubMed Central · Cited by 95
Chamberlain, M. C. (1993) · Archives of Neurology · doi:10.1001/archneur.1993.00540030027009 · Cited by 94
Kan, V. L., Bennett, J. E., Amantea, M., Smolskis, M. C., McManus, E., Grasela, D. M., & Sherman, J. W. (1991) · The Journal of Infectious Diseases · doi:10.1093/infdis/164.2.418 · Cited by 93
Negishi, T., Koizumi, F., Uchino, H., Kuroda, J.-I., Kawaguchi, T., Naito, S., & Matsumura, Y. (2006) · British Journal of Cancer · doi:10.1038/sj.bjc.6603311 · Cited by 92
The Key Extended Entry Program (KEEP): a methadone treatment program for opiate-dependent inmates.
Tomasino, V., Swanson, A. J., Nolan, J., & Shuman, H. I. (2001) · PubMed · Cited by 91
Alakhova, D. Y., Zhao, Y., Li, S., & Kabanov, A. V. (2013) · PLoS ONE · doi:10.1371/journal.pone.0072238 · Cited by 91
Conlin, A. K., Seidman, A. D., Bach, A. M., Lake, D. E., Dickler, M. N., D’Andrea, G. M., Traina, T. A., Danso, M. A., Brufsky, A., Saleh, M. N., et al. (2010) · Clinical Breast Cancer · doi:10.3816/cbc.2010.n.036 · Cited by 91
Dritschilo, A., Huang, C. H., Rudin, C. M., Marshall, J. L., Collins, B., Dul, J. L., Zhang, C., Kumar, D., Gokhale, P. C., Ahmad, A., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-1260 · Cited by 91
Mehta, R. T., Hopfer, R. L., McQueen, T. J., Juliano, R. L., & Lopez‐Berestein, G. (1987) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.31.12.1901 · Cited by 89
In vitro antifungal activities of amphotericin B and liposome-encapsulated amphotericin B
Hopfer, R. L., Mills, K., Mehta, R. T., Lopez‐Berestein, G., Fainstein, V., & Juliano, R. L. (1984) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.25.3.387 · Cited by 89
Evaluation of dendrimer SPL7013, a lead microbicide candidate against herpes simplex viruses
Gong, E. Y., Matthews, B. R., McCarthy, T. D., Chu, J., Holan, G., Raff, J. W., & Sacks, S. L. (2005) · Antiviral Research · doi:10.1016/j.antiviral.2005.08.004 · Cited by 86
Vadhan‐Raj, S., Strauss, W., Ford, D. C., Bernard, K. E., Boccia, R. V., Li, J., & Allen, L. F. (2013) · American Journal of Hematology · doi:10.1002/ajh.23582 · Cited by 85
Kottschade, L. A., Suman, V. J., Pérez, D. G., McWilliams, R. R., Kaur, J. S., AMATRUDA, T. T., Geoffroy, F. J., Gross, H. M., Cohen, P. A., Jaslowski, A. J., et al. (2012) · Cancer · doi:10.1002/cncr.27760 · Cited by 84
Hong, R., & Tseng, Y. (2001) · Cancer · doi:10.1002/1097-0142(20010501)91:9<1826::aid-cncr1203>3.0.co;2-j · Cited by 84
Mehta, R. T., Hopfer, R. L., Gunner, L. A., Juliano, R. L., & Lopez‐Berestein, G. (1987) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.31.12.1897 · Cited by 82
Gonzalez-Angulo, A. M., Meric‐Bernstam, F., Chawla, S. P., Falchook, G. S., Hong, D. S., Akçakanat, A., Chen, H., Naing, A., Fu, S., Wheler, J. J., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-3110 · Cited by 82
Sasaki, Y., Nishina, T., Yasui, H., Goto, M., Muro, K., Tsuji, A., Koizumi, W., Toh, Y., Hara, T., & Miyata, Y. (2014) · Cancer Science · doi:10.1111/cas.12419 · Cited by 82
Hansel, D. E., Platt, E., Orloff, M. S., Harwalker, J., Sethu, S., Hicks, J. L., Marzo, A. D., Steinle, R., Hsi, E. D., Theodorescu, D., et al. (2010) · American Journal Of Pathology · doi:10.2353/ajpath.2010.090872 · Cited by 82
Phase I and pharmacologie study of liposomal daunorubicin (DaunoXome)
Guaglianone, P. P., Chan, K. K., Delaflor–Weiss, E., Hanisch, R., Jeffers, S., Sharma, D., & Muggia, F. M. (1994) · Investigational New Drugs · doi:10.1007/bf00874439 · Cited by 81
Sanders, S. W., Buchi, K. N., Goddard, M. S., Lang, J. K., & Tolman, K. G. (1991) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.35.6.1029 · Cited by 80
Teneriello, M. G., Tseng, P. C., Crozier, M., Encarnacion, C. A., Hancock, K. C., Messing, M. J., Boehm, K. A., Williams, A., & Asmar, L. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.9548 · Cited by 80
Hetzel, D. J., Strauss, W., Bernard, K. E., Li, Z., Urboniene, A., & Allen, L. F. (2014) · American Journal of Hematology · doi:10.1002/ajh.23712 · Cited by 79
Amphotericin B lipid soluble formulations versus amphotericin B in cancer patients with neutropenia
Johansen, H. K., & Gøtzsche, P. C. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd000969.pub2 · Cited by 79
Stinchcombe, T. E., Socinski, M. A., Walko, C. M., O’Neil, B. H., Collichio, F. A., Ivanova, A., Mu, H., Hawkins, M., Goldberg, R. M., Lindley, C. M., et al. (2007) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-007-0423-x · Cited by 79
Socinski, M. A., Manikhas, G., Stroyakovskiy, D., Makhson, A. N., Валентинович, Ч. С., Орлов, С. В., Yablonsky, P. K., Bhar, P., & Iglesias, J. (2010) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3181d5e39e · Cited by 78
McKiernan, J. M., Barlow, L. J., Laudano, M. A., Mann, M. J., Petrylak, D. P., & Benson, M. C. (2011) · The Journal of Urology · doi:10.1016/j.juro.2011.03.129 · Cited by 78
Deeken, J. F., Slack, R. S., Weiss, G. J., Ramanathan, R. K., Pishvaian, M. J., Hwang, J. J., Lewandowski, K., Subramaniam, D. S., He, A. R., Cotarla, I., et al. (2012) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-012-2048-y · Cited by 78
Micellization of cisplatin (NC-6004) reduces its ototoxicity in guinea pigs
Baba, M., Matsumoto, Y., Kashio, A., Cabral, H., Nishiyama, N., Kataoka, K., & Yamasoba, T. (2011) · Journal of Controlled Release · doi:10.1016/j.jconrel.2011.07.026 · Cited by 77
Gaur, S., Wang, Y., Kretzner, L., Chen, L., Yen, T., Wu, X., Yuan, Y., Davis, M. E., & Yen, Y. (2014) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2014.04.003 · Cited by 77
Preclinical toxicology of a novel polymeric antitumour agent: HPMA copolymer-doxorubicin (PK1)
Duncan, R., Coatsworth, J. K., & Burtles, S. S. (1998) · Human & Experimental Toxicology · doi:10.1177/096032719801700204 · Cited by 76
Novel SN-38–Incorporated Polymeric Micelle, NK012, Strongly Suppresses Renal Cancer Progression
Sumitomo, M., Koizumi, F., Asano, T., Horiguchi, A., Ito, K., Asano, T., Kakizoe, T., Hayakawa, M., & Matsumura, Y. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-6532 · Cited by 76
The safety and efficacy of ferumoxytol therapy in anemic chronic kidney disease patients
Spinowitz, B., Schwenk, M. H., Jacobs, P. M., Bolton, W. K., Kaplan, M. R., Charytan, C., & Galler, M. (2005) · Kidney International · doi:10.1111/j.1523-1755.2005.00598.x · Cited by 74
Paclitaxel Poliglumex (PPX-Xyotax) and Concurrent Radiation for Esophageal and Gastric Cancer
DiPetrillo, T. A., Milas, L., Evans, D. L., Akerman, P., Ng, T., Miner, T., Cruff, D., Chauhan, B., Iannitti, D. A., Harrington, D. T., et al. (2006) · American Journal of Clinical Oncology · doi:10.1097/01.coc.0000224494.07907.4e · Cited by 74
Cohen, C. R., Brown, J., Moscicki, A., Bukusi, E. A., Paull, J. R., Price, C. F., & SHIBOSKI, S. C. (2011) · PLoS ONE · doi:10.1371/journal.pone.0016258 · Cited by 74
Prince, M. R., Zhang, H. L., Chabra, S. G., Jacobs, P. M., & Wang, Y. (2003) · Journal of X-Ray Science and Technology · doi:10.3233/xst-2003-00092 · Cited by 73
The distribution and radiation effects of intravenously administered colloidal Au198 in man
Root, S. W., Andrews, G. A., Kniseley, R. M., & Tyor, M. P. (1954) · Cancer · doi:10.1002/1097-0142(195409)7:5<856::aid-cncr2820070506>3.0.co;2-a · Cited by 73
Kanra, G., Marchisio, P., Feiterna‐Sperling, C., Gaedicke, G., Lazar, H., Durrer, P., Kürsteiner, O., Herzog, C., Kara, A., & Principi, N. (2004) · The Pediatric Infectious Disease Journal · doi:10.1097/00006454-200404000-00005 · Cited by 72
Hopewell, J. W., Duncan, R., Wilding, D., & Chakrabarti, K. (2001) · Human & Experimental Toxicology · doi:10.1191/096032701682693017 · Cited by 72
New use of metals as nanosized radioenhancers.
Pottier, A., Borghi, E., & Lévy, L. (2014) · PubMed · Cited by 72
The activation of human monocytes by liposome-encapsulated muramyl dipeptide analogues.
Lopez‐Berestein, G., Mehta, K., Mehta, R. T., Juliano, R. L., & Hersh, E. M. (1983) · The Journal of Immunology · doi:10.4049/jimmunol.130.4.1500 · Cited by 72
Amphotericin B and its delivery by liposomal and lipid formulations
Gates, C., & Pinney, R. J. (1993) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/j.1365-2710.1993.tb00605.x · Cited by 70
Potent antitumor effect of SN‐38‐incorporating polymeric micelle, NK012, against malignant glioma
Kuroda, J., Kuratsu, J., Yasunaga, M., Koga, Y., Saito, Y., & Matsumura, Y. (2008) · International Journal of Cancer · doi:10.1002/ijc.24171 · Cited by 69
Ueno, T., Endo, K., Hori, K., Ozaki, N., Tsuji, A., Kondo, S., Wakisaka, N., Murono, S., Kataoka, K., Kato, Y., et al. (2014) · International Journal of Nanomedicine · doi:10.2147/ijn.s60564 · Cited by 69
Ahlström, K. H., Johansson, L. O. M., Rodenburg, J. B., Ragnarsson, A., Åkeson, P., & Børseth, A. (1999) · Radiology · doi:10.1148/radiology.211.3.r99jn10865 · Cited by 69
Gaur, S., Chen, L., Yen, T., Wang, Y., Zhou, B., Davis, M. E., & Yen, Y. (2011) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2011.09.007 · Cited by 68
Mehta, J., Kelsey, S. M., Chu, P., Powles, R., Hazel, D. L., Riley, U., Evans, C., Newland, A. C., Treleaven, J., & Singhal, S. (1997) · Bone Marrow Transplantation · doi:10.1038/sj.bmt.1700842 · Cited by 68
Gabizón, A., Amitay, Y., Tzemach, D., Gorin, J., Shmeeda, H., & Zalipsky, S. (2011) · Journal of Controlled Release · doi:10.1016/j.jconrel.2011.11.019 · Cited by 66
Cytotoxicity and physicochemical properties of hafnium oxide nanoparticles
Field, J. A., Luna‐Velasco, A., Boitano, S. A., Shadman, F., Ratner, B. D., Barnes, C. R., & Sierra‐Álvarez, R. (2011) · Chemosphere · doi:10.1016/j.chemosphere.2011.04.067 · Cited by 65
Toxicity of parenteral iron dextran therapy
Burns, D. L., & Pomposelli, J. J. (1999) · Kidney International · doi:10.1046/j.1523-1755.1999.055suppl.69119.x · Cited by 65
Prolongation of drug exposure in cerebrospinal fluid by encapsulation into DepoFoam.
Kim, S., Khatibi, S., Howell, S. B., McCully, C. L., Balis, F. M., & Poplack, D. G. (1993) · PubMed · Cited by 65
Effects of Sterols on the Therapeutic Efficacy of Liposomal Amphotericin B in Murine Candidiasis
Lopez‐Berestein, G., Mehta, R. T., Hopfer, R. L., Mehta, K., Hersh, E. M., & Juliano, R. L. (1983) · Cancer Drug Delivery · doi:10.1089/cdd.1983.1.37 · Cited by 65
Liposomal doxorubicin in combination with bortezomib for relapsed or refractory multiple myeloma.
Ning, Y. M., He, K., Dagher, R. N., et al. (2007) · PubMed · Cited by 64
Hamilton, E. P., Kimmick, G. G., Hopkins, J. O., Marcom, P. K., Rocha, G., Welch, R. A., Broadwater, G., & Blackwell, K. (2013) · Clinical Breast Cancer · doi:10.1016/j.clbc.2013.08.003 · Cited by 62
Moscicki, A., Kaul, R., Ma, Y., et al. (2011) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0b013e31823f2aeb · Cited by 61
Alikhani, M., Alikhani, Z., Raptis, M., & Graves, D. T. (2004) · Journal of Cellular Physiology · doi:10.1002/jcp.20067 · Cited by 60
Sabbatini, P. J., Sill, M. W., O’Malley, D. M., Adler, L. M., & Secord, A. A. (2008) · Gynecologic Oncology · doi:10.1016/j.ygyno.2008.07.049 · Cited by 60
Reynolds, C. H., Barrera, D., Jotte, R. M., Spira, A. I., Weissman, C., Boehm, K. A., Pritchard, S., & Asmar, L. (2009) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3181c0a2f4 · Cited by 60
Nakajima, T. E., Yasunaga, M., Kano, Y., Koizumi, F., Kato, K., Hamaguchi, T., Yamada, Y., Shirao, K., Shimada, Y., & Matsumura, Y. (2008) · International Journal of Cancer · doi:10.1002/ijc.23381 · Cited by 58
PSMA Ligand Conjugated PCL-PEG Polymeric Micelles Targeted to Prostate Cancer Cells
Jin, J., Sui, B., Gou, J., Liu, J., Tang, X., Xu, H., Zhang, Y. X., & Jin, X. (2014) · PLoS ONE · doi:10.1371/journal.pone.0112200 · Cited by 58
Recent developments in palliative chemotherapy for locally advanced and metastatic pancreas cancer
Bayraktar, S., Bayraktar, U. D., & Rocha-Lima, C. M. (2010) · World Journal of Gastroenterology · doi:10.3748/wjg.v16.i6.673 · Cited by 58
Yardley, D. A., Raefsky, E. L., Castillo, R., Lahiry, A., LoCicero, R., Thompson, D. S., Shastry, M., Burris, H. A., & Hainsworth, J. D. (2011) · Clinical Breast Cancer · doi:10.1016/j.clbc.2011.04.002 · Cited by 57
Markman, M. M., Moon, J., Wilczynski, S. P., López, A. M., Rowland, K. M., Michelin, D. P., Lanzotti, V. J., Anderson, G. L., & Alberts, D. S. (2009) · Gynecologic Oncology · doi:10.1016/j.ygyno.2009.11.026 · Cited by 57
Nightingale, S. D., Saletan, S., Swenson, C. E., Lawrence, A. J., Watson, D., Pilkiewicz, F. G., Silverman, E. G., & Cal, S. (1993) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.37.9.1869 · Cited by 54
Numbenjapon, T., Wang, J., Colcher, D. M., Schluep, T., Davis, M. E., Duringer, J., Kretzner, L., Yen, Y., Forman, S. J., & Raubitschek, A. A. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-2619 · Cited by 52
Infante, J. R., Keedy, V. L., Jones, S. F., Zamboni, W. C., Chan, E. W., Bendell, J. C., Lee, W., Wu, H., Ikeda, S., Kodaira, H., et al. (2012) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-012-1960-5 · Cited by 49
Shepard, D. R., Dreicer, R., Garcia, J., Elson, P. J., Magi‐Galluzzi, C., Raghavan, D., Stephenson, A. J., & Klein, E. A. (2009) · The Journal of Urology · doi:10.1016/j.juro.2008.11.121 · Cited by 48
Verschraegen, C. F., Skubitz, K. M., DAUD, A. I., Kudelka, A. P., Rabinowitz, I., Allievi, C., Eisenfeld, A. J., Singer, J. W., & Oldham, F. B. (2008) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-008-0813-8 · Cited by 46
Johnson, W. K., Stoupis, C., Torres, G. M., Rosenberg, E. B., & Ros, P. R. (1996) · Magnetic Resonance Imaging · doi:10.1016/0730-725x(95)02044-t · Cited by 46
Ott, P. A., Chang, J., Madden, K. M., Kannan, R., Muren, C., Escano, C., Cheng, X., Shao, Y., Mendoza, S., Gandhi, A., et al. (2012) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-012-1995-7 · Cited by 46
Predicted 30‐year protection after vaccination with an aluminum‐free virosomal hepatitis A vaccine
BOVIER, P. A., Bock, J., Farinelli, T., Frösner, G., Glaus, J., Herzog, C., & Loutan, L. (2010) · Journal of Medical Virology · doi:10.1002/jmv.21883 · Cited by 45
Juliano, R. L., Lopez‐Berestein, G., Hopfer, R. L., et al. (1985) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1985.tb18416.x · Cited by 41
Nemunaitis, J. J., Cunningham, C. C., Senzer, N. N., Gray, M., Oldham, F. B., Pippen, J., Mennel, R. G., & Eisenfeld, A. J. (2005) · Cancer Investigation · doi:10.1080/07357900500359935 · Cited by 41
Yamamoto, Y., Hyodo, I., Takigahira, M., Koga, Y., Yasunaga, M., Harada, M., Hayashi, T., Kato, Y., & Matsumura, Y. (2013) · International Journal of Cancer · doi:10.1002/ijc.28651 · Cited by 40
Neoadjuvant Paclitaxel Poliglumex, Cisplatin, and Radiation for Esophageal Cancer
DiPetrillo, T. A., Suntharalingam, M., Ng, T., et al. (2011) · American Journal of Clinical Oncology · doi:10.1097/coc.0b013e318201a126 · Cited by 39
Heusler, R. C. H., Wight, E., & Marinček, B. (1995) · Journal of Magnetic Resonance Imaging · doi:10.1002/jmri.1880050404 · Cited by 38
Limited Toxicity of Prolonged Therapy with High Doses of Amphotericin B Lipid Complex
Kline, S., Larsen, T., Fieber, L. A., Fishbach, R., Greenwood, M. F., Harris, R. C., Kline, M. W., Tennican, P. O., & Janoff, E. N. (1995) · Clinical Infectious Diseases · doi:10.1093/clinids/21.5.1154 · Cited by 37
Pegylated Liposomal Doxorubicin: A Guide to Its Use in Various Malignancies
Lyseng-Williamson, K. A., Duggan, S. T., & Keating, G. M. (2013) · BioDrugs · doi:10.1007/s40259-013-0070-1 · Cited by 36
Multifunctional Synthetic Poly( l -Glutamic Acid)–Based Cancer Therapeutic and Imaging Agents
Melancon, M. P., & Li, C. (2011) · Molecular Imaging · doi:10.2310/7290.2011.00007 · Cited by 36
Kaklamani, V., Siziopikou, K. P., Scholtens, D. M., Lacouture, M. E., Gordon, J., Uthe, R., Meservey, C., Hansen, N. M., Khan, S. A., Jeruss, J. S., et al. (2011) · Breast Cancer Research and Treatment · doi:10.1007/s10549-011-1411-8 · Cited by 33
Seidman, A. D., Conlin, A. K., Bach, A. M., Moynahan, M. E., Lake, D. E., Forero, A., Wright, G. S., Hackney, M. H., Clawson, A., Norton, L., et al. (2013) · Clinical Breast Cancer · doi:10.1016/j.clbc.2013.02.008 · Cited by 32
Pharmacogenetics of Antiangiogenic and Antineovascular Therapies of Age-Related Macular Degeneration
Agosta, E., Lazzeri, S., Orlandi, P., Figus, M., Fioravanti, A., Desidero, T. D., Sartini, M. S., Nardi, M., Danesi, R., & Bocci, G. (2012) · Pharmacogenomics · doi:10.2217/pgs.12.77 · Cited by 32
Phase I study of the novel taxane CT-2103 in patients with advanced solid tumors
Veronese, M. L., Flaherty, K. T., Kramer, A., Konkle, B. A., Morgan, M. A., Stevenson, J. P., & O'Dwyer, P. J. (2005) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-004-0938-3 · Cited by 31
Richards, D., Richards, P. D., Bodkin, D., Neubauer, M., & Oldham, F. B. (2005) · Clinical Lung Cancer · doi:10.3816/clc.2005.n.039 · Cited by 28
McArthur, H. L., Rugo, H. S., Nulsen, B., Hawks, L. C., Grothusen, J., Melisko, M., Moasser, M. M., Paulson, M., Traina, T. A., Patil, S. N., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-1969 · Cited by 28
Carol, H., Fan, M., Harasym, T. O., Boehm, I., Mayer, L. D., Houghton, P. J., Smith, M. A., & Lock, R. B. (2014) · Pediatric Blood & Cancer · doi:10.1002/pbc.25133 · Cited by 25
Hu, X., Wang, B., Sun, S., Tang, L., Zhang, J., Lv, F., Wang, Z., Wang, L., Zhang, Q., Zheng, C., et al. (2014) · International Journal of Nanomedicine · doi:10.2147/ijn.s58275 · Cited by 25
Direct Gene Transfer for the Understanding and Treatment of Human Disease
Plautz, G. E., Nabel, E. G., Fox, B. A., Yang, Z., Jaffe, M. L., GORDON, D., Chang, A. E., & Nabel, G. J. (1994) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1994.tb21709.x · Cited by 25
Moreno‐Aspitia, A., & Perez, E. A. (2005) · Clinical Breast Cancer · doi:10.3816/cbc.2005.n.042 · Cited by 23
A phase I trial of nab-paclitaxel, gemcitabine, and capecitabine for metastatic pancreatic cancer
Ko, A. H., Truong, T., Kantoff, E., Jones, K., Dito, E., Ong, A., & Tempero, M. A. (2012) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-012-1979-7 · Cited by 21
Rubin, P., & Levitt, S. H. (1964) · PubMed · Cited by 19
Gergis, U. S., Roboz, G. J., Shore, T. B., Ritchie, E. K., Mayer, S. A., Wissa, U., McKenna, M., Christos, P. J., Pearse, R. N., Mark, T. M., et al. (2013) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2013.04.013 · Cited by 18
Drug News and Trial Developments
(1995) · Aids Patient Care · doi:10.1089/apc.1995.9.306 · Cited by 17
Mehta, R. T., Lopez‐Berestein, G., Hopfer, R. L., et al. (1985) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.28.4.511 · Cited by 16
Hatz, C., Beck, B. R., Steffen, R. J., Genton, B., D’Acremont, V., Loutan, L., Hartmann, K., & Herzog, C. (2011) · Vaccine · doi:10.1016/j.vaccine.2011.04.099 · Cited by 13
Yanagihara, K., Takigahira, M., Kubo, T., Ochiya, T., Hamaguchi, T., & Matsumura, Y. (2014) · Therapeutic Delivery · doi:10.4155/tde.13.143 · Cited by 11
(1995) · PubMed · Cited by 8
Hentschel, M., Mirtsch, S., Jordan, A., Wust, P., Vogl, T., Semmler, W., Wolf, K. ‐., & FELIX, R. (1997) · International Journal of Hyperthermia · doi:10.3109/02656739709056431 · Cited by 7
Cited by
Analysis of nanoparticle delivery to tumours
Wilhelm, S., Tavares, A. J., Dai, Q., Ohta, S., Audet, J., Dvorak, H. F., & Chan, W. C. W. (2016) · Nature Reviews Materials · doi:10.1038/natrevmats.2016.14 · Cited by 5,218
Reactive Oxygen Species (ROS)-Based Nanomedicine
Yang, B., Chen, Y., & Shi, J. (2019) · Chemical Reviews · doi:10.1021/acs.chemrev.8b00626 · Cited by 2,443
Reactive oxygen species generating systems meeting challenges of photodynamic cancer therapy
Zhou, Z., Song, J., Nie, L., & Chen, X. (2016) · Chemical Society Reviews · doi:10.1039/c6cs00271d · Cited by 2,098
Ulbrich, K., Holá, K., Šubr, V., Bakandritsos, A., Tuček, J., & Zbořil, R. (2016) · Chemical Reviews · doi:10.1021/acs.chemrev.5b00589 · Cited by 1,730
Diverse Applications of Nanomedicine
Pelaz, B., Alexiou, C., Alvarez-Puebla, R. A., Alves, F., Andrews, A. M., Ashraf, S., Balogh, L. P., Ballerini, L., Bestetti, A., Brendel, C., et al. (2017) · ACS Nano · doi:10.1021/acsnano.6b06040 · Cited by 1,350
Metadata
- Authors
- Min, Y., Caster, J. M., Eblan, M. J., & Wang, A. Z.
- Venue
- Chemical Reviews
- Publisher
- American Chemical Society (ACS)
- Published
- 2015-06-19
- Volume
- 115
- Issue
- 19
- Pages
- 11147-11190
- ISSN
- 0009-2665 (ISSN-L)
- 1520-6890
- OpenAlex
- W2297044638
- Cited by
- 772
- References
- 325
- FWCI
- 2.99
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.